• Vaccine Ontology ID: VO_0004259
• Type: DNA vaccine
• Status: Research
• Antigen: The DNA vaccine constructs were developed based on the gene sequences of the gp140 envelope, p55 Gag, Nef, and Tat proteins from the HIV-2UC2 isolate (GenBank accession number U38293) (Locher et al., 2004).
• gag gene engineering:
  • Type: DNA vaccine construction
  • Detailed Gene Information: Click Here.
• nef gene engineering:
  • Type: DNA vaccine construction
  • Detailed Gene Information: Click Here.
• tat gene engineering:
  • Type: DNA vaccine construction
  • Detailed Gene Information: Click Here.
• env gene engineering:
  • Type: DNA vaccine construction
  • Detailed Gene Information: Click Here.
• Adjuvant:
  • VO ID: VO_0001337
• Adjuvant:
  • VO ID: VO_0001294
• Vector: pND-14 (Locher et al., 2004)
• Immunization Route: Intramuscular injection (i.m.)

Baboon Response

• Vaccination Protocol: Each baboon was immunized four times with the experimental or control DNA constructs formulated with Vaxfectin. The time intervals were chosen to permit maturation of the immune response (Locher et al., 2004).
• Challenge Protocol: One month after the fourth immunization, the baboons were challenged twice (6 h apart) by the intravaginal route using 50 baboon infectious dosages (30,000 tissue culture infectious dosages) of HIV-2UC2/9429 for a total of 100 baboon infectious dosages. This virus isolate is a more virulent variant of the HIV-2UC2 isolate and was recovered from a baboon with an AIDS-like disease (Locher et al., 2004).
• Efficacy: At 2 weeks post-HIV-2 challenge, viral loads ranged from 100 (below the threshold of detection) to 81,000 viral RNA copies in the plasma, with the lowest average viral loads in the group of baboons that received the HIV-2 DNA without the genetic adjuvants (a mean of 852 copies/ml), followed by the group of baboons the received the HIV-2 DNA and the genetic adjuvants (a mean of 2499 copies/ml) (Locher et al., 2004).